Table II. B cell dominance of IL-10/GFP+ expression by splenic leukocytes after diverse in vivo stimulia.
| Cell Type | LPS | CpG | Goat anti-IgD | MCMV |
|---|---|---|---|---|
| CD19+ | 89.7 ± 0.5 | 84.1 ± 1.1 | 83.9 ± 0.9 | 59.4 ± 2.7 |
| TCR+ | 5.0 ± 0.4 | 7.3 ± 0.7 | 10.8 ± 1.3 | 22.2 ± 2.2 |
| CD11chigh | 0.2 ± 0.02 | 0.3 ± 0.03 | 0.8 ± 0.2 | 2.8 ± 0.2 |
| CD11b+ | 3.8 ± 0.5 | 3.6 ± 0.3 | 1.1 ± 0.1 | 5.4 ± 0.2 |
| NK1.1+ | 1.7 ± 0.1 | 1.8 ± 0.2 | 0.8 ± 0.1 | 0.6 ± 0.1 |
a
Vert-X mice were challenged with LPS (E. coli K12; 20 μg i.v.; harvested at 48 h); CpG (ODN1826, 50 μg i.v.; 24 h); Goat anti-mouse IgD (400 μl i.p.; 6 d); and MCMV Smith strain (1 × 105 pfu, subcutaneously in the foot pad; 7 d). Splenic leukocytes were analyzed by flow cytometry. The data shown depict the percentage (± SEM) of the total number of GFP+ cells accounted for by cells expressing the indicated surface markers. N.B., As cells can express more than one of these markers, the total does not always add up to 100%. Data depicted represent the mean percentages of GFP+ cell types in 8 (LPS), 3 (CpG), 7 (anti-IgD) or 5 (MCMV) mice, respectively.